HOME >> BIOLOGY >> NEWS
Rimonbant shows promise in addressing multiple risk factors

Quebec City, Canada, March 9, 2004 - Results of a Phase III clinical trial (RIO-Lipids or Rimonabant In Obesity) comparing rimonabant, the first drug in a new class called Selective CB1 Blockers (or SCB1Bs), to placebo found that overweight or obese patients with untreated dyslipidemia (high triglycerides, low HDL-cholesterol) lost almost 20 lbs (8.6 kg) when treated for a year with rimonabant 20mg. Weight loss was accompanied by a decrease in waist size of 3.4 inches (9.1 cm) demonstrating a significant reduction in abdominal obesity, an independent marker for heart disease. Dramatic improvements were also seen in lipid profile with a 23% increase in HDL-cholesterol (good cholesterol) and a 15% decrease in triglycerides. Improvements in glucose tolerance and insulin levels were also observed. In another important finding, the number of patients diagnosed at baseline with metabolic syndrome,1 who were treated with rimonabant 20mg, was reduced by half. The drug was also found to be safe and well-tolerated.

Rimonabant works by inhibiting the CB1 receptor, one of two receptors found in a newly described physiological system called the Endocannabinoid System (EC System), believed to play a critical role in the regulation of food intake and energy expenditure.

"While the weight loss was clinically relevant, what is truly remarkable in the RIO-Lipids study is the significant effect rimonabant had on improving associated cardiovascular risk factors," said Jean-Pierre Despr's, principal investigator for RIO-Lipids and Professor in the Department of Food Sciences and Nutrition and Medicine at Laval University, and Director of Research at the Quebec Heart Institute located at the Laval Hospital Center in Quebec City, Canada. "Rimonabant appears to have a direct effect on fat cells which may be contributing to the beneficial effects of this drug on abdominal obesity and associated risk factors. Couple this with the markedly
'"/>

Contact: Glenn Lehrman
glenn.lehrman@ketchum.com
917-533-5998
Ketchum
9-Mar-2004


Page: 1 2 3 4 5 6

Related biology news :

1. New study shows hope for treating inhalant abuse
2. Chemical derived from vitamin-E shows early promise as cancer drug
3. Cancer vaccine based on pathogenic listeria bacteria shows promise targeting metastases
4. Trial shows which brain cancer patients benefit from temozolomide
5. New research shows plants can shuffle and paste gene pieces to generate genetic diversity
6. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
7. Simian virus 40 not associated with non-Hodgkin lymphoma, study shows
8. A probable cause for high blood pressure identified - shows links with diabetes
9. Blue marlin in gulf have high mercury levels, A&M study shows
10. New research shows air pollution can reduce childrens lung function
11. Pneumococcal vaccine reduces ear infections, pneumonia, new study shows

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Rimonbant shows promise addressing multiple risk factors

(Date:5/20/2015)... 20, 2015 ... announced the addition of the  "5-year ... Recognition Market"  report to their offering.  ... service analyses trends in the iris ... commercial sectors, globally. Despite hardware pricing ...
(Date:5/19/2015)... DUBLIN , May 19, 2015 /PRNewswire/ ... ) has announced the addition of the  ... their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A ... provides an in-depth analysis of the current ... introduction of gene-based tests, their working principles ...
(Date:5/11/2015)... Calif. , May 11, 2015  Synaptics ... of human interface solutions, today announced the appointment ... President and Chief Financial Officer, reporting to ... replaces Synaptics, current Chief Financial Officer, Kathleen ... 2014. Mr. Ali brings extensive ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
(Date:5/20/2015)... 19, 2015 Research and Markets ( ... "Global Cell Therapy Market Outlook 2020 " report ... in tissue and regenerative medicine is expected to have ... which could help in the growth of deregulated organs. ... they are unable to form new tissue or sometimes ...
(Date:5/20/2015)... 2015 The global genotyping market is ... the forecast period of 2015 to 2020 to reach ... in drug discovery and development process and to provide ... addition to this,heavy investments by key manufacturers to offer ... propelling market growth. Browse 113 market data tables & ...
(Date:5/20/2015)... (PRWEB) May 20, 2015 Agricultural firm ... anniversary of its acquisition of Tiger-Sul. Since the ... (Calgary Alberta, Canada) in May 2005, H.J. Baker has ... build it into a comprehensive portfolio of product offerings ... of H.J. Baker and the innovation of Tiger-Sul, transforming ...
(Date:5/20/2015)... 2015  Haemonetics Corporation (NYSE: HAE ) announced ... will present at The Jefferies 2015 Global Healthcare Conference ... 1 st , 2015 at 8:30am Eastern time.  ... live via webcast at: http://wsw.com/webcast/jeff88/hae ... ) is a global healthcare company dedicated to providing ...
Breaking Biology Technology:Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5Agricultural Firm H.J. Baker & Bro., Inc., Celebrates 10 Years Since Acquisition Of Tiger-Sul 2Agricultural Firm H.J. Baker & Bro., Inc., Celebrates 10 Years Since Acquisition Of Tiger-Sul 3
Cached News: